AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
11 juil. 2023 07h00 HE
|
AccuStem Sciences, Inc
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE)...
[Latest] Global Breast Cancer Diagnostics Market Size/Share Worth USD 7.5 Billion by 2030 at a 6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
01 févr. 2023 15h30 HE
|
Custom Market Insights
Sandy, Utah, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Diagnostics Market Size, Trends, and Insights By Type (Imaging,...
Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
10 nov. 2021 16h05 HE
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly...
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
24 juin 2020 16h20 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m....
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
05 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Further Strengthens Business Development Team with Key Hire PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced...